You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

~ Buy the BREO ELLIPTA (fluticasone furoate; vilanterol trifenatate) Drug Profile, 2024 PDF Report in the Report Store ~

BREO ELLIPTA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Breo Ellipta patents expire, and when can generic versions of Breo Ellipta launch?

Breo Ellipta is a drug marketed by Glaxo Grp Ltd and is included in one NDA. There are seven patents protecting this drug.

This drug has two hundred and fourteen patent family members in thirty-two countries.

The generic ingredient in BREO ELLIPTA is fluticasone furoate; vilanterol trifenatate. There are twenty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fluticasone furoate; vilanterol trifenatate profile page.

DrugPatentWatch® Generic Entry Outlook for Breo Ellipta

Breo Ellipta was eligible for patent challenges on May 10, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 26, 2029. This may change due to patent challenges or generic licensing.

Annual sales in 2021 were $2.8bn, indicating a strong incentive for generic entry.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for BREO ELLIPTA?
  • What are the global sales for BREO ELLIPTA?
  • What is Average Wholesale Price for BREO ELLIPTA?
Drug patent expirations by year for BREO ELLIPTA
Drug Prices for BREO ELLIPTA

See drug prices for BREO ELLIPTA

Drug Sales Revenue Trends for BREO ELLIPTA

See drug sales revenues for BREO ELLIPTA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BREO ELLIPTA
Generic Entry Date for BREO ELLIPTA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INHALATION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BREO ELLIPTA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Baylor Research InstitutePhase 4
Chiesi Farmaceutici S.p.A.Phase 4
Luis Puente MaestuPhase 4

See all BREO ELLIPTA clinical trials

US Patents and Regulatory Information for BREO ELLIPTA

BREO ELLIPTA is protected by seven US patents and three FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of BREO ELLIPTA is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting BREO ELLIPTA

Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl) phenol
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Phenethanolamine derivatives for treatment of respiratory diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Medicament dispenser
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Medicament dispenser
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Manifold for use in medicament dispenser
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Medicament dispenser
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Medicament dispenser
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting BREO ELLIPTA

NEW STRENGTH
Exclusivity Expiration: ⤷  Sign Up

PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷  Sign Up

NEW PATIENT POPULATION
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275-003 May 12, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275-001 May 10, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275-002 Apr 30, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275-003 May 12, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BREO ELLIPTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275-002 Apr 30, 2015 ⤷  Sign Up ⤷  Sign Up
Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275-001 May 10, 2013 ⤷  Sign Up ⤷  Sign Up
Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275-002 Apr 30, 2015 ⤷  Sign Up ⤷  Sign Up
Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275-001 May 10, 2013 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for BREO ELLIPTA

When does loss-of-exclusivity occur for BREO ELLIPTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Croatia

Patent: 0191257
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 21914
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 00950
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 00950
Patent: PRÉPARATIONS PHARMACEUTIQUES COMPRENANT 4-{(1R)-2-[(6-{2-[(2,6-DICHLOROBENZYL)OXY]ÉTHOXY}HEXYL)AMINO]-1-HYDROXYÉTHYL}-2-(HYDROXYMÉTHYL)-PHÉNOL (PHARMACEUTICAL FORMULATIONS COMPRISING 4-{(1 R)-2-[(6-{2-[(2,6-DICHLOROBENZYL)OXY]ETHOXY}HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL)
Estimated Expiration: ⤷  Sign Up

Patent: 78169
Patent: PRÉPARATIONS PHARMACEUTIQUES COMPRENANT 4-{(1R)-2-[(6-{2-[(2,6-DICHLOROBENZYL)OXY]ÉTHOXY}HEXYL)AMINO]-1-HYDROXYÉTHYL}-2-(HYDROXYMÉTHYL)-PHÉNOL (PHARMACEUTICAL FORMULATIONS COMPRISING 4-{(1 R)-2-[(6-{2-[(2,6-DICHLOROBENZYL)OXY]ETHOXY}HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 45917
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 09985
Estimated Expiration: ⤷  Sign Up

Patent: 12518663
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 00950
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 00950
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 00950
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 00950
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 39352
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BREO ELLIPTA around the world.

Country Patent Number Title Estimated Expiration
South Africa 200300929 17.Beta.-carbothioate 17.Alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents. ⤷  Sign Up
Australia 2003244506 PHARMACEUTICAL FORMULATION COMPRISING AN AQUEOUS SUSPENSION OF AN ANDROSTANE DERIVATIVE FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC CONDITIONS ⤷  Sign Up
Colombia 5310550 NUEVO DERIVADO DE ANDROSTANO ANTIINFLAMATORIO, SU POLIMORFO, SUS FORMAS CRISTALINAS SOLVATADAS, COMPOSICIONES FARMACEUTIAS, PROCESO PARA PREPARARLO, INTERMEDIARIO ⤷  Sign Up
South Africa 200410295 Medicament dispenser. ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for BREO ELLIPTA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1425001 CR 2014 00021 Denmark ⤷  Sign Up PRODUCT NAME: VILANTEROL ELLER ET SALT ELLER SOLVAT DERAF, HERUNDER VILANTEROL TRIFENATAT; REG. NO/DATE: EU/1/13/886/001-006 20131114
1519731 92269 Luxembourg ⤷  Sign Up PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
1305329 C01305329/01 Switzerland ⤷  Sign Up PRODUCT NAME: FLUTICASON FUROAT; REGISTRATION NUMBER/DATE: SWISSMEDIC 57968 19.12.2007
1305329 326 Finland ⤷  Sign Up
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.